Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Top Cited Papers
- 1 March 2002
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 359 (9312), 1121-1122
- https://doi.org/10.1016/s0140-6736(02)08158-8
Abstract
Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p< 0·0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.Keywords
This publication has 5 references indexed in Scilit:
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002
- Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirClinical Therapeutics, 2001
- Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populationsHuman Immunology, 2001
- Genetic susceptibility to adverse drug reactionsTrends in Pharmacological Sciences, 2001
- Pharmacogenetics and future drug development and deliveryThe Lancet, 2000